Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

Anyone peculating why Leo is letting B/Absssi sit on the shelf and not progressing it along via a regional size pharma partner for a limited geographic area like Japan, or Korea or heck even Asia, anything to prove its value by generating results? Even if it's for free with the partner paying all related expenses it's better than letting the competition leap frog us while we sit like an elf on a shelf waiting for Santa Clause. The all or nothing approach seems fraught with issues as far as I'm concerned.
The same could be said for any of our drugs for limited indications I suppose, but B/Absssi is far enough along that I would think a regional player would take a swing at it.